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Pollutant exposure during development has been shown to induce developmental 
malformations. For example, penis deformities are the most common birth defects occurring in 
boys born in the United States, and are associated with exposure to endocrine disrupting 
chemicals. Hypospadias occurs when the urethra does not open at the distal tip of the penis, 
but rather along the shaft, and is associated with decreased anogenital distance (AGD). The 
incidence rate of hypospadias has doubled over the past 50 years. Currently there are no 
known prenatal supplements to protect the fetus from hypospadias-inducing pollutants. 
However, if we can up-regulate endogenous detoxifying enzymes within the mother, fetus, or 
placenta we should reduce the effects of toxicants on the fetus. It has been proposed that 
sulforaphane, a derivative of broccoli, could be developed as such a preventative prenatal 
supplement because of its ability to increase detoxification and decrease oxidative stress. 
Removal of the pollutant from maternal and fetal circulation before it can impact development 
is a viable and general method to reduce pollutant-induced diseases. Indeed, sulforaphane 
supplementation to pregnant mice exposed to the anti-androgen vinclozolin at concentrations 
(125 mg/kg) that demasculinize genital development can increase AGD, and reduce 
hypospadias severity (most effective sulforaphane dose is 45 mg/kg). Here I test the hypothesis 
that sulforaphane at 45 mg/kg can decrease the potency of vinclozolin. To test this I conducted 
a dose response experiment were I dosed pregnant CD1 mice with either 0 or 45 mg/kg of 
sulforaphane and crossed those doses with either 0, 50, 75, 100, and 125 mg/kg of Vinclozolin 
and measured hypospadias incidence and severity, and proximal urethral opening size. 
Sulforaphane exposure significantly lowered the dose response to vinclozolin across all 
endpoints. This work shows that sulforaphane can reduce the severity and incidence of 
hypospadias in the mouse model, and takes the first step required to develop a prenatal 
supplement that will protect humans from pollutant-induced birth defects.  
 
Introduction 
Environmental pollutants are ubiquitously distributed in soil, water, crops, and the 
atmosphere. All humans are exposed to toxins throughout their life through ingestion, 
inhalation or dermal contact (Aris, 2014) (Sandau et al., 2000) (Thomas et al., 2006). Exposure 
to environmental pollutants occur inevitably but at varying levels based on individual lifestyle, 
geographic location, socioeconomic disparities, occupation, and many other factors. Exposure 
to these toxins can dysregulate several physiological processes systemically. Dysregulation can 
be especially impactful on the developing fetus (Fernandez, et al., 2007). Evidence indicates 
that embryonic exposure to environmental pollutants has more severe effects because fetuses 
have not yet developed protective detoxification mechanisms that is present in the adult (K. 
McCoy, unpublished data). The structures fetuses are developing also require hormones, whose 
concentrations and function are commonly affected by pollutant exposure (WHO/UNEP, 2013). 
In addition, during the fetal stage systems and physiological pathways are developed that will 
be used throughout the individual’s lifetime, thus developmental alterations can have lifelong 
repercussions (Lee & Blumberg, 2019). 
Several congenital malformations such as hypospadias and cryptorchidism, and adult 
diseases, such as cardiovascular disease, developmental immunotoxicity, and obesity, are 
linked to embryonic exposure to environmental pollutants such as endocrine disrupting 
chemicals (EDCs) (Xing & Bai, 2018) (Hanson & Gluckman, 2008) (Bernal & Jirtle, 2010) (DeWitt 
& Patisaul, 2018). These data also support the hypothesis that adult diseases have fetal origins 
(Lucas, Fewtrell, & Cole, 1999). Stimuli, such as environmental pollutant exposures, during 
critical fetal developmental windows have negative health implications that transcend into 
adulthood and across a lifespan (Barker & Osmond, 1986) (Lee & Blumberg, 2019). 
Endocrine disrupting chemicals (EDCs) are environmental contaminants that disrupt 
many aspects of endocrine signaling and regulation. Many studies show that exposure to EDCs 
can induce malformations and various pathologies (Bergman, Heindel, Jobling, Kidd, & Zoeller, 
2012) (Ormond, et al., 2009) (Fernandez, et al., 2007). One defect associated with prenatal 
exposure to EDCs is hypospadias, a congenital abnormality of the penis. Hypospadias occurs 
when the urethra does not open at the distal tip of the penis but rather ventrally along the 
shaft (Baskin & Ebbers, 2006). Pollutant-induced hypospadias can be caused by androgen 
receptor antagonists during critical developmental periods (Wilson, Blystone, Hotchkiss, Rider, 
& Gray Jr, 2008). This antiandrogenic exposure disrupts the androgen signaling pathway at the 
cellular level (Wilson, Blystone, Hotchkiss, Rider, & Gray Jr, 2008). Hypospadias is one of the 
most common birth defects in the United States occurring in up to 1% male newborns each 
year (State Birth Defects Surveillance Program). Data from the Metropolitan Atlanta Congenital 
Defects Program (MACDP) and nationwide Birth Defects Monitoring Program (BDMP) showed 
the incidence of hypospadias approximately doubled from the 1970s to the 1980s (Paulozzi, 
Erickson, & Jackson, 1997) with more severe cases increasing at a faster rate than mild cases. 
Hypospadias incidence has continued to rise and is now the most common birth defect in 20 of 
the 37 US states that were recently surveyed (State Birth Defects Surveillance Program). 
Hypospadias occurs in a range of severities, with mild cases having an urethral that 
opens near the distal tip and severe cases having an urethral exit at or below the base of the 
penis (Amato & McCoy, 2016 ; Leung & Robson, 2007). Severe cases can result in painful 
erections, reduced fertility, difficulty in urination, and can even have lasting negative 
psychological effects (Baskin & Ebbers, 2006). Surgical correction of the external genitalia 
remains one of the most challenging procedures due to the amount of soft tissue and excessive 
scar tissue that interferes with urethral function (Barbagli, De Angelis, Palminteri, & Lazzeri, 
2006). The option for surgical treatment is a difficult one for families to make and can cause 
high emotional strain. Even with treatment, pain, psychological symptoms and negative 
experiences persist into adulthood (Adams & Bracka, 2016).  
Even though EDCs induce congenital defects, such as hypospadias, few studies have 
been conducted to develop treatments to decrease exposure to pollutants during 
development. Due to the wide prevalence of EDCs it is unrealistic to expect pregnant mothers 
to fully protect the fetus by preventing exposure. Therefore, identifying a prenatal supplement 
that protects the fetus from general environmental toxicant exposure is vital.  
Environmentally induced birth defects have the potential to be preventable. For 
example, poor nutrition and reduced circulating foliate concentrations induce neural tube 
defects, and prenatal folic acid supplementation has significantly reduced these and other birth 
defects. Recently, it was proposed that sulforaphane, a nutrient derived from cruciferous 
vegetables, such as broccoli, could be developed as a general preventative agent to protect the 
fetus from toxicant exposure (Philbrook et al., 2014 ). Sulforaphane is known to activate 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-induced detoxification and antioxidant 
proteins (Houghton et al, 2016) (Jahan et al, 2014).Sulforaphane is seen as a promising 
bioactive phytochemical under preclinical evaluation and clinical trials as a preventative for 
diverse disorders including several types of cancer, cardiovascular disease, neurodegenerative 
diseases, and diabetes (Oliveri et al., 2018) 
EDC induced hypospadias is an excellent model to study the protective nature of 
prenatal supplementation because it is a common birth defect, gives a consistent phenotype, 
and is inducible in the laboratory setting. The mouse has been extensively used to study the 
mechanisms through which EDCs induce hypospadias. For example, the dose and exposure time 
that induces 100% hypospadias has been determined for the model EDC vinclozolin (Amato et 
al. 2018). The certainty of inducing hypospadias allows fetal mice to be sampled before the 
abnormality develops so that the mechanisms that cause hypospadias can be investigated. 
Another strength of the mouse as a model to study EDC-induced hypospadias is that a validated 
protocol for scoring hypospadias severity has been established (Amato & McCoy, 2016 ). Also, 
penis development in the mouse has been well characterized (Harding et al., 2011) (McMahon 
et al.). Both male and female genitalia arise from a bipotential genital tubercle and during early 
urogenital development a proximal urethral opening (PUO) forms in both sexes. In females, the 
PUO is reconstructed into the vagina. In males the PUO is closed by mesenchymal infiltration 
which septates the urethral plate. In addition to closing the PUO, the mesenchymal infiltration 
extends to the distal tip of the penis and pushes the urethra into the middle of the penis. 
Vinclozolin exposure disrupts this process and results in reduction or absence of mesenchymal 
infiltration (Kurzrock et al., 1999), causing the PUO to remain open, and urethra to open 
proximally on the shaft of the penis. 
In this manuscript, I test the hypothesis that sulforaphane will decrease vinclozolin 
potency on hypospadias incidence and severity, and PUO size by decreasing its affects across 
vinclozolin doses (e.g., sulforaphane will reduce the vinclozolin dose response).  
 
Methodology 
 Pregnant CD-1 dams were gavaged from embryonic day (E) 13.5-E16.5 with vinclozolin 
only, vinclozolin+sulforaphane, sulforaphane only, or a corn oil (CO) solvent control (N=5 dams 
per treatment). On E18.5, the dams were humanely sacrificed. Embryos were individually 
weighed and measured for total body length, anogenital distance, and genitalia were preserved 
in 10% neutral buffered formalin until they were evaluated for hypospadias incidence and 
severity. To score hypospadias severity genitalia of each pup was photographed in a standard 
position and evaluated using the standardized scoring system (M.O.U.S.E, (Amato & McCoy, 
2016 )). After photographs were taken genitalia samples were processed for histological 
evaluation of the PUO.  
 To begin histological processing embryo genitalia were dehydrated, and embedded in 
paraffin wax using standard procedures (Presnell & Schreibman, 1997). Samples were then 
cross sectioned at 10 um and stained with hematoxylin and eosin. Sections were 
microscopically evaluated 
using a Leica DME light 
microscope. Measures of 
masculinization including 
genitalia height, urethral 
length, and septation and 
PUO height, were collected 
for analysis to analyze 
internal morphological 
structures. To analyze these 
length measurements, the 
base of the penis was defined 
as the first section where the 
genitalia was disconnected 
from the perineum, 
establishing the first section 
for data collection. The 
height of the genitalia was 
calculated as the sum of all 
the sections between the 
base of the penis and the 
distal tip multiplied by the 
section thickness of 10 μm. Likewise, the urethral length was determined by counting the 
number of sections, from the base to the first section to the urethral opening (indicated by 
black arrow in figure 1) multiplied by section thickness. Septation height was collected as the 
Figure 1. Normal penis development results in the urethral opening (black arrow) that 
occurs at the distal tip of the penis, while in hypospadias the urethral opening (black 
arrow) occurs on the shaft of the penis. (A)The base of the penis is collected as the first 
section where the genitalia was disconnected from the perineum. Septation (solid line) 
is indicated by mesenchymal cells (lightly stained) that split the epithelial cells (more 
darkly stained). (B) PUO (dotted arrow) height was collected from the base to the 
section where it closed. 
(A) (B) 
number of sections that include a separated (septated) urethral and epithelial seam epidermis 
starting at the base of the penis ad multiplied by the section thickness (10 um)(shown in 
Normal panel of figure 1 by the black bar). PUO height (reported here) was determined as the 
number of sections between the PUO start and end multiplied by the section thickness (10 um). 
An example of the PUO start section can be seen in the Hypospadias panel of Figure 1, with the 
dash line indicating the location the section was taken from and the bottom of the panel 
displaying the histological section. 
All data were analyzed in R statistical programming environment v. 3.4.3 (R Core Team, 
2016) using lme4 package (Bates et al., 2005). Assumptions of homoscedasticity, normality, and 
dispersion were tested by interpreting residual plots, qqplots, and dispersion coefficients, 
respectively. Hypospadias incidence was analyzed using a binomial generalized linear mixed 
model (glmm). Hypospadias severity was analyzed using a Gaussian glmm. PUO height data 
were analyzed as raw counts of 10 µm histological sections using a Poisson glmm. To avoid 
pseudoreplication, dam was treated as a random effect in all models with pups being nested 
within dam (Bolker et al, 2009).  
 
Results 
For all endpoints there was 
an increase in effect with 
vinclozolin dose. However, a 
significant interaction 
between sulforaphane 
presence and vinclozolin dose 
occurred where the slope of 
the vinclozolin dose response 
was shallower (reduced) in 
the presence of 
sulforaphane. Both 
hypospadias incidence 
(FIGURE 2A, df=1, 2=7.6019, 
LRT p=0.005381) and 
hypospadias severity (FIGURE 
2B, df=1, 2=4.8313, LRT 
p=0.027948) were reduced 
across all doses of vinclozolin 
in the presence of 
sulforaphane 
supplementation.  Males 
Figure 2. Sulforaphane (SFN) rescues penis development. Embryos exposed to 
vinclozolin and no sulforaphane (circles) reliably develop hypospadias (A). 
Supplementing VCZ exposed dams with 45mg/kg sulforaphane (triangles) reduces 
hypospadias incidence (A) and severity (B). Sulforaphane supplementation decreased 
incidence and height of  PUO 
exposed to vinclozolin in this study had high incidences and large PUOs when compared to 
males exposed to both vinclozolin and sulforaphane (Figure 2C, Figure 3, df=1, 2=17.4581, LRT 
p=2.937 x 10-5). In the presence  
of sulforaphane at 45 mg/kg the presence of a PUO was completely eliminated in all but the 
highest vinclozolin dose, while 50% of the 50 mg/kg and 100% of the 75 and 100 mg/kg 
vinclozolin only exposed embryos had PUOs. Additionally, In the cases where vinclozolin + 
sulforaphane exposed animals had PUOs, the PUO height was reduced (Figure 2C) relative to 
vinclozolin and no sulforaphane supplementation.  
 
Discussion 
 Sulforaphane reduces vinclozolin-induced hypospadias severity and incidence, and 
increases mesenchymal infiltration to fill in the PUO in our model system. Sulforaphane 
significantly lowered the potency of vinclozolin by the reducing the dose response relationship 
in the sulforaphane supplemented embryos relative to the vinclozolin only treatment. 
Sulforaphane, therefore, is a strong candidate for use as a prenatal supplement to protect 
developing embryos from contaminants that induce hypospadias, and it should be evaluated in 
more detail for use in humans.  
More research must be conducted into the underlying mechanism through which this 
rescue effect occurs. In this investigation it is unclear how and where this hypospadias rescue is 
originating. For example, we have no evidence that sulforaphane is directly affecting genitalia 
development. However, a new study showed that rats with hypospadias have reduced 
expression of Nrf2 the transcription factor through which sulforaphane is thought to work. It is 
possible that sulforaphane is mediating detoxification of vinclozolin. This detoxification could 
be occurring in the liver or in the placenta. The other possibility for how this rescue is occurring 
is sulforaphane mediated reduction of oxidative stress. This could be occurring in the testis, and 
Figure 3. Prenatal sulforaphane supplementation rescues genital morphology in the presence of the anti-androgenic EDC 
vinclozolin. Control embryos exhibit normal penis development, with the urethral opening (red arrow) being present at the distal 
tip (A). In Vinclozolin treated animals, the embryos display hypospadias, with the urethral opening (red arrow) being present on 
the ventral shaft of the penis. Males exposed to vinclozolin also had a high incidence of PUO (white arrow), a structure seen in 
female morphology (B). Vinclozolin+Sulforaphane treated individuals showed a rescued phenotype, with the urethral exit being 
returned closer to the distal tip and no PUO, except in extremely high doses of vinclozolin (C). 
 
thereby increase testosterone synthesis, which would decrease the ability of vinclozolin to 
compete for the androgen receptor. To truly understand the mechanisms inducing the 
sulforaphane mediated rescue of vinclozolin-induced hypospadias, tissue level analyses need to 
be conducted.   
Hypospadias is the most common birth defect in the United states and occurs up to one 
percent of males born each year (State Birth Defect Survalence Program, 2016). Genetic 
mutations cannot account for the recent rise in hypospadias occurrence in the population. For 
example, one study showed that after removing patients with known genetic causes of 
hypospadias, the remaining 74% of cases were exposed to higher toxicants (Kalfa, et al., 2015). 
In fact, mothers with occupational exposures to phthalates, pesticides, and other 
xenoestrogens have a higher risk of their children having hypospadias (Ormond, et al., 2009) 
(Baskin et al., 2001) (Aho et al., 2003). Here we show that sulforaphane protects the fetus from 
the pesticide vinclozolin, we believe, however, that sulforaphane will be generally protective. 
Although it is not currently used as a prenatal supplement, sulforaphane is known to 
increase detoxification efficiency (Egner et al., 2014) (Houghton et al, 2016) (Kensler, et al., 
2012) (Abiko et al., 2018). The ability of sulforaphane to upregulate antioxidant and detoxifying 
enzymes is being clinically investigated in a variety of contexts. For example, sulforaphane is 
being investigated for treatment in autism (Bent et al., 2018) and in the protection of cardiac 
muscle in ischemia–reperfusion (Piao et al., 2010). Sulforaphane has also been used to increase 
the metabolism of air pollution in China (Kensler, et al., 2012), to reduce DNA damage induced 
by fried meat (Shaughnessy, et al., 2011), and is a general dietary supplement that can be 
purchased at local drug retails. Therefore, sulforaphane is generally useful and available. As a 
test of its general use as a protective prenatal supplement, future work should test its 
effectiveness to protect developing fetuses from other contaminants and mixtures that are 
known to induce congenital abnormalities. 
Environmental EDCs are responsible for many cases of hypospadias and lifestyle and 
occupation can increase susceptibility (Ormond, et al., 2009). My data suggests that if we can 
augment natural detoxification pathways we can reduce contaminant exposure and protect the 
fetus during development. The development of a prenatal therapy to reduce the incidence of 
this common birth defect will be exciting and extremely beneficial.  
This study combined with past sulforaphane studies provide important steps toward the 
development of targeted prenatal therapeutics to reduce environmental toxicant induced birth 
defects such as hypospadias. In a world were environmental pollutants are increasing, being 
able to reduce environmental toxicant loads will also have implications far beyond decreasing 
one of the most common birth defects. This potential prenatal therapy could allow us to 
protect future generations from the harmful programing induced by pollutant exposure. We are 
especially hopeful that sulforaphane will protect against a multitude of contaminants and will 
empower women to protect their developing babies from the ubiquitous contaminants that we 
are unavoidably exposed.  
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